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Abstract 
Background: In China, mesangial proliferative glomerulonephritis (MsPGN) is one of the most common kidney dis-
eases. In this study, we treated a rat model of chronic anti-Thy-1 MsPGN with Shenhua Tablet and evaluated whether 
the tablet was able to protect the kidney function. Thirty-six Wistar rats were randomly divided into six groups: (1) 
Sham surgery (Sham); (2) anti-Thy-1 nephritis model (Thy-1); (3) anti-Thy-1 nephritis model + irbesartan-treated (Irb); 
(4) anti-Thy-1 nephritis model + low-dose of Shenhua Tablet (SHL); (5) anti-Thy-1 nephritis model + medium-dose of 
Shenhua Tablet (SHM); (6) anti-Thy-1 nephritis model + high-dose of Shenhua Tablet (SHH).
Results: Thirteen weeks after drug treatment, urinary proteins were quantified and renal pathological changes were 
thoroughly examined at the time point of 24 h. Meanwhile, the expression levels of p-Erk1/2, cyclin D1 and p21 at 
the renal cortex were also tested. The levels of urinary proteins and total cholesterol in the blood were significantly 
reduced in rats treated with any drug tested in this study. The level of triglyceride was significantly reduced in all three 
Shenhua Tablet-treated groups. Renal pathomorphological scores were significantly improved in groups of Irb, SHM 
and SHH. Mesangial cell proliferation was significantly inhibited in any drug-treated group. p-Erk1/2 and cyclin D1 
were downregulated whereas p21 was upregulated in the renal cortex.
Conclusions: Our study indicated that Shenhua Tablet is able to inhibit the abnormal proliferation of mesangial cells 
and to prevent kidney damage, which is likely associated with downregulation of p-Erk1/2 and reduced activity of its 
downstream target-cyclin D1.
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Background
Mesangial proliferative glomerulonephritis (MsPGN) 
is characterized by widespread mesangial cell prolifera-
tion and an accumulation of extracellular matrix, and is 
the most common type of glomerulonephritis globally 
[1, 2]. Abnormal proliferation of mesangial cells plays an 
important role in the onset and progression of glomerlu-
lar lesion [3]. Abnormally proliferative mesangial cells are 
able to release mediators of inflammation and mesangial 
matrix, which often cause severe glomerulosclerosis and 
interstitial fibrosis, resulting in irreversible progressive 
glomerulosclerosis, eventually leading to end-stage renal 
disease (ESRD) [4]. Therefore, to inhibit mesangial cell 
proliferation is a great therapeutic strategy for MsPGN 
and searching for such drugs is urgently needed for the 
treatment of this disease. Clinically, MsPGN patients 
especially IgAN patients, are currently treated with drugs 
such as hormones, cyclophosphamide, azathioprine, 
mycophenolate mofetil, leflunomide, and so on. However, 
these drugs often have toxic side effects, which largely 
compromise their clinical applications. Therefore, it has 
become critical to seek for effective treatments actively 
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and further understand the mechanism underlying how 
these drugs protect the kidney functions [5, 6].
Shenhua Tablet has been widely used in clinical set-
tings for many years. Clinical evidence has shown that 
this drug is able to reduce the level of proteinuria in 
patients with IgA nephropathy, and greatly improve 
the life quality of patients without serious adverse reac-
tions [7]. However, whether Shenhua Tablet can protect 
the kidney functions of MsPGN patients remains com-
pletely unclear. This study aimed to investigate the role 
of Shenhua Tablet in the treatment of chronic anti-Thy-1 
MsPGN, and to explore the possible mechanism under-
lying the improvement in kidney function after Shenhua 
Tablet treatment.
Results
Shenhua Tablet reduces the proteinuria level in rats 
with chronic anti‑Thy‑1 nephritis
The levels of urinary protein in 24  h were recorded for 
each group over the experimental process. We observed 
that the urinary proteins were gradually increased in 
each group after being given Thy-1 antibody four times 
through intravenous injection at the time points W1, W3, 
W5 and W7 (p < 0.05). At the time point W11 (21 days 
after the last injection of Thy-1 antibody at W7), urinary 
proteins in 24 h in experimental groups were still signifi-
cantly higher than that in the Sham group, indicating that 
the animal model of chronic anti-Thy-1 nephritis was 
reliably established [8, 9]. At the last time point W20, the 
urinary proteins in 24 h in all drug-treated groups were 
significantly lower (p  <  0.01) than that in the group of 
anti-Thy-1. However, there was no significant difference 
between SHM group and Irb group in terms of levels of 
urinary proteins in 24 h (p = 0.14), which suggested that 
SHM and Irb functioned similarly in reducing the urinary 
proteins in 24 h for experimental rats (Fig. 1).
The effect of Shenhua Tablet on the renal function 
and biochemical indices in blood
The levels of serum creatinine in each group were also 
determined at the last time point W20. As observed, the 
level of serum creatinine in anti-Thy-1 group was sig-
nificantly higher compared with that in the Sham group 
(p = 0.003). However, the levels of serum creatinine were 
not significantly changed (p  >  0.05) in all drug-treated 
groups in contrast to that in the Thy-1 group, which dem-
onstrated that irbesartan and Shenhua Tablet of any dose 
in this study were unable to reduce the level of serum 
creatinine in rats with anti-Thy-1 nephritis (Fig. 2).
At W20, the levels of serum albumin were not signifi-
cantly increased (p > 0.05) whereas the levels of total cho-
lesterol in blood were strikingly reduced (p < 0.05) in all 
drug-treated groups, compared with those in the Thy-1 
group. However, the levels of total cholesterol were not 
significantly different among all drug-treated groups 
(p > 0.05). It was noteworthy that Shenhua Tablet of any 
dose (low, medium or high) was able to reduce the levels of 
triglyceride significantly (p < 0.05). However, there was no 
significant differences when treated with different doses of 

























Fig. 1 The levels of urinary protein in 24 h were monitored for each group over the experimental process (week 1, 3, 5, 7, 11 and 20 after injection 
of Thy-1 antibody). At the last time point W20, the urinary proteins in 24 h in all drug-treated groups were significantly lower (p < 0.01) than that in 
the Thy-1 group. Values were expressed as mean ± SD. * p< 0.05, ** p< 0.01 vs. Thy-1; # p< 0.05, ## p< 0.01 vs. Irb group
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Shenhua Tablet inhibits proliferation of mesangial cells 
in rats with anti‑Thy‑1 nephritis and improves renal 
pathological scores
The histopathological changes in glomeruli were exam-
ined under the microscope after PAS staining. At W20, 
the changes including increased proliferation of glomeru-
lar cells (p  <  0.01) and mesangial cells, accumulation of 
mesangial matrix, widening of mesangial region, com-
pression, deformation even occlusion of the capillary 
lumen, were observed in the Thy-1 group but not in the 
Sham group (Fig. 4a, b). Thirteen weeks after drug treat-
ment, the proliferation of mesangial cells was significantly 
reduced; the widening of mesangial regions and accu-
mulation of mesangial matrix were strikingly improved 
and the capillary lumen also recovered back to normal 
as compared with those in the Thy-1 group (Fig. 4a). No 
increase in the number of mesangial cells and accumu-
lation of mesangial matrix were observed in the Sham 
group (Fig. 4a). At W20, the number of glomerular cells 
in all drug-treated groups, including Irb (p < 0.05), SHL 
(p < 0.01), SHM (p < 0.01) and SHH (p < 0.01), was sig-
nificantly reduced compared with that in the anti-Thy-1 
group (Fig. 4a, b).
PCNA (proliferating cell nuclear antigen) is well-
known as a marker of cell proliferation which localizes 
in the nucleus. PCNA is barely detectable in the glo-
meruli of the Sham group. However, it was significantly 
increased at W20 in the Thy-1 group, compared with the 
Sham group (p < 0.01). Thirteen weeks after drug treat-
ment, PCNA-positive cells were significantly reduced in 
all drug-treated groups when compared with those in the 
Thy-1 group (p < 0.01) (Fig. 4c, d).
Renal pathological score is generally used to compre-
hensively evaluate the kidney damage. At W20, the score 
was significantly higher in the Thy-1 group compared 
with that in the Sham group (p =  0.001); However, this 
score was significantly decreased in three drug-treated 
groups, including Irb (p =  0.01), SHM (p =  0.014) and 
SHH (p = 0.017), when compared with that in the anti-
Thy-1 group (Fig. 4e).
Shenhua Tablet downregulates p‑Erk1/2 and cyclin 
D1 while upregulating p21 in the renal cortex of rats 
with anti‑Thy‑1 nephritis
As Shenhua Tablet was able to inhibit the proliferation of 
mesangial cells, improve pathological scores and reduce 
the proteinuria level in rats with anti-Thy-1 nephritis, we 
then went on to explore the possible molecular mechanism 
underlying how this drug worked. We first investigated 
the expression level of p-Erk1/2 to see whether Erk/Mapk 
signaling pathway was activated; we also examined cyclin 
D1 and p21 to see whether these cell cycle regulatory pro-
teins were dysregulated. The data indicated that expression 
levels of p-Erk and cyclin D1 were strikingly increased in 
the Thy-1 group (p < 0.01) while the level of p21 was largely 
reduced (p < 0.05) when compared with the Sham group. 
However, in all groups with drug treatment, the expres-
sion levels of p-Erk were significantly reduced compared 
to that in the anti-Thy-1 group (p < 0.01). It is noteworthy 
that the expression levels of p-Erk in all Shenhua Tablet-
treated groups were even more reduced compared with 
that in the Irb-treated group. We also observed that in the 
drug-treated groups, the expression level of cyclin D1 was 






























Fig. 2 The levels of serum creatinine in each groups at different time points. The levels of serum albumin were quantified in all six groups at differ-
ent time points (week 1, 3, 5, 7 and 20 after injection of Thy-1 antibody). Values were expressed as mean ± SD. * p< 0.05, ** p< 0.01 vs. Thy-1
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group (p < 0.01). Moreover, we noticed that the expression 
of cyclin D1 was similar between the Irb group and SHM 
group, which suggested that Irb and Shenhua Tablet with 
medium dose had the same effect on the expression of cyc-
lin D1. In addition, the expression levels of p21 in groups 
of Irb, SHL and SHM were significantly higher than that in 
Thy-1 group (p < 0.05) while there was no significant dif-
ference among all drug-treated groups (p > 0.05) (Fig. 5).
Discussion
Abnormal proliferation of mesangial cells is an important 
pathological feature of multiple immune-mediated glo-
merular diseases; continuous mesangial cell proliferation 
eventually leads to irreversible glomerulosclerosis, and 
even progresses to renal failure [4]. MsPGN, including 
IgAN and non-IgA MsPGN, is the most common glo-










































































Fig. 3 The effect of Shenhua Tablet on the biochemical indices in blood. a The levels of serum albumin were quantified in all six groups at different 
time points (week 1, 3, 5, 7 and 20 after injection of Thy-1 antibody). b The levels of total cholesterol in blood were quantified in all six groups at 
different time points mentioned above. c The levels of triglyceride were quantified in all six groups at different time points mentioned above. Values 
were expressed as mean ± SD. * p< 0.05, ** p< 0.01 vs. Thy-1. n = 6
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disease (ESRD) [10]. Therefore, inhibition of mesangial 
cell proliferation is a great strategy to treat proliferative 
glomerular diseases. Hence, searching for such inhibitors 
can have important clinical implications.
In the past 20 years, although mesangial cell prolif-
eration signaling pathways have become clearer, spe-
cific drugs used to inhibit the proliferation of mesangial 
cells are still poorly available. Currently, clinical applica-
tions are only limited to a few drugs, such as hormones, 
cytotoxics, and so on. With the development of Chinese 
medicine theory, a number of classical prescriptions, 
special prescriptions and drugs, patent medicines, and 
their extracts or injections have been proved to be effec-
tive in the treatment of human diseases in some respects, 
which indicates traditional Chinese medicine can also be 
used in the treatment of chronic kidney disease, such as 
MsPGN. With accumulating evidences and more stud-
ies in clinical and basic research, the efficacy of Chinese 
medicine in the treatment of chronic kidney diseases has 
been well recognized in the national and international 
medical field. It has been clear that Chinese medicine 
and integrative medicine are effective approaches to treat 
patients with chronic kidney disease (including MsPGN). 



























































Fig. 4 Shenhua Tablet inhibits proliferation of mesangial cells in rats with anti-Thy-1 nephritis and improves renal pathological scores. a Histological 
changes in PAS-stained sections at W20 (×400 magnification). Scale bar 50 µm. b The total number of glomerular cross section in the six groups. c 
PCNA-positive cells in the groups at W20. Scale bar 50 µm. d The PCNA labeling index in all six groups. The index was calculated according to the 
ratio of PCNA positive cells to total glomerular cells. e Histological scores of the renal lesions in all six groups. Values were expressed as mean ± SD. 
* p< 0.05, ** p< 0.01 vs. Thy-1
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placebo-controlled clinical experiments have shown 
that Shenhua Tablet is able to reduce proteinuria level 
in IgA nephropathy patients deficient with Qi and Yin, 
and to improve their clinical symptoms without serious 
adverse reactions [7]. However, the mechanism under-
lying remains poorly understood. To date, only a few 
studies show that through toll-like receptors (TLRs), 
treatment of Shenhua Tablet is able to reduce the secre-
tion of inflammatory cytokines, thereby improving the 
ischemia-reperfusion-induced acute kidney injury [11]. 
Currently, no experimental data demonstrate whether 
Shenhua Tablet is able to inhibit mesangial cell prolifera-
tion in rats with anti-Thy1 nephritis.
In this study, we first report that Shenhua Tablet is able 
to inhibit mesangial cell proliferation and protect kidneys 
in rats with chronic anti-Thy-1 MsPGN, a classic animal 
model widely used for human MsPGN. The greatest fea-
ture of this model is that the renal damages are irrevers-
ible, which is different from the acute anti-Thy-1 MsPGN 
model in which mesangial cell proliferation and matrix 
accumulation are reversible. To some extent this model 
can mimic human chronic MsPGN [12], which is an 
important consideration to improve ‘bench to bedside’ 
applicability. However, chronic anti-Thy-1 nephritis in 
the rat is caused by abnormal deposition of IgG in glo-
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Fig. 5 Shenhua Tablet downregulates p-Erk1/2 and cyclin D1 while upregulating p21 in the renal cortex of rats with anti-Thy-1 nephritis. a Western 
blot was performed to detect the expression levels of p-Erk1/2, cyclin D1 and p21 in all drug-treated groups as well as the controls. b Quantifica-
tion of the cyclin D1, p21 and p-Erk1/2. Expression level of p-Erk1/2 was normalized with total Erk1/2 while cyclin D1 and p21 were normalized with 
beta-actin. Each bar represents the mean ± SD of six rats. * p< 0.05, ** p< 0.01 vs. Thy-1; # p< 0.05, ## p< 0.01 vs. Irb group
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MsPGN, is primarily caused by the deposition of IgA in 
the glomeruli [13], together with the species and genetic 
differences between rat and human, therefore the results 
obtained from this model can not be directly used to 
predict human IgAN. Regardless of this limitation, so 
far anti-Thy-1 nephritis model is the most representa-
tive animal model used to search for drug targets against 
mesangial cell proliferation [9].
To perform an in vivo study, we orally treated the rats 
with Shenhua Tablets (low, medium and high dose) once 
a day for 13 weeks and assessed the drug effect. The data 
showed that Shenhua Tablets was able to reduce the 
level of proteinuria and total cholesterol significantly, 
which was comparable to the therapeutic effect observed 
in the positive control-irbesartan group. In this study, 
we noticed that the level of serum creatinine in the rats 
with anti-Thy-1 nephritis was not significantly reduced 
when Shenhua Tablet of any dose was applied. In the 
future study, we may extend the time for drug treatment 
following the time point of W20, and re-examine if the 
level of creatinine becomes significant different between 
the drug-treated group and anti-Thy-1 group. We are 
also interested in testing whether protein uptake in the 
proximal tubules is increased in our future studies. We 
also found that Shenhua Tablet could strikingly inhibit 
glomerular cell proliferation based on the data obtained 
from renal pathological scores, glomerular cell count-
ing, PCNA-positive glomerular cell counting, and so on. 
Previous studies have shown that ERK activity plays an 
important role in mesangial cell proliferation, and this 
activity is also essential to cell cycle progression [14, 
15]. ERK can translocate into the nucleus, phosphoryl-
ate and activate a number of transcription factors, such 
as AP-1, ELK-1, SAP, and then promote cell prolifera-
tion [16]. Once the ERK/MAPK pathway is activated, the 
downstream target genes, such as cyclin D1, an impor-
tant regulator of cell cycle at the G1 phase [17], will be 
activated as well. Furthermore, another important cyc-
lin, termed CDK4, needs to complex with its regulatory 
subunit cyclin D1 to be functional [18, 19]. In acute anti-
Thy-1 nephritis model, cyclin D1, CDK4 and other cell 
cycle-related proteins are all upregulated when mesangial 
cells are abnormally proliferating. In  vitro experiments 
also confirmed that mesangial cell proliferation was strik-
ingly inhibited when the expression level of cyclin D1 
was decreased following removal of the serum or PDGF 
stimulation [19]. Therefore, we examined one of the key 
proteins in the Erk/Mapk signaling pathway-Erk1/2, and 
the cell cycle regulatory proteins in the Shenhua Tablet-
treated groups. We found that treatment with Shenhua 
Tablet downregulated the phosphorylation of Erk1/2 and 
cyclin D1 while upregulating p21 in the rat model. There-
fore, the possible mechanism underlying Shenhua Tablet 
inhibits the mesangial cell proliferation is that this drug 
specifically deactivates Erk in the Erk/Mapk pathway, 
thus downregulates cell cycle regulatory proteins, and 
ultimately inhibits cell proliferation. These findings have 
offered a therapeutic potential to Shenhua Tablet in the 
treatment of chronic glomerulonephritis, particularly for 
those MsPGN-derived diseases, such as IgAN. In addi-
tion, patients with chronic kidney disease often have an 
abnormal metabolism in blood lipids [20]. Lipids have 
a direct role in glomerular injury, and may also result in 
glomerular mesangial cell activation and proliferation 
[21], and dyslipidemia has been known to be one of the 
risk factors for the deterioration of renal function. Inter-
estingly, we also found that Shenhua Tablet with different 
doses could all significantly reduce the levels of both tri-
glycerides and total cholesterol whereas the positive con-
trol Irb could only reduce the level of total cholesterol but 
not of triglycerides. The molecular mechanism underly-
ing this observation needs to be further explored.
Conclusions
In this study, we discovered that Shenhua Tablet is able to 
reduce the level of 24 h proteinuria and the degree of kid-
ney injury in the chronic anti-Thy-1 nephritis rat model. 
These functional improvements by Shenhua Tablet treat-
ment in the injured kidneys might be directly associated 
with the deactivation of Erk signaling pathway, modu-
lations of downstream cell cycle regulatory proteins, 




Compound Shenhua Tablets (0.6 g/tablet, extracted from 
at least 3.095  g of crude drug) were nicely provided by 
Hunan Traditional Chinese Medicine Research Institute 
(Batch No. 20090910). The main components in this tab-
let include Radix Astragali, Fruit of Glossy Privet, Cur-
cuma and Honeysuckle. The non-standardized product 
number in People’s Liberation Army is F01012 (2006). 
irbesartan was provided by Hangzhou Sanofi-Aventis 
Minsheng Pharmaceutical Co., Ltd. (Batch number: 
0A008; approval number: Zhunzi J20080061). The drug 
powder was mixed and suspended with 0.4  % CMC-Na 
(Wako Pure Chemical Industries, Ltd., Japan) solution 
prior to intragastric administration to rats.
Animal model of chronic anti‑Thy‑1 nephritis
Seven-week-old male Wistar rats (SPF grade,  ~200  g) 
were purchased from Beijing Vital River Laboratory Ani-
mal Technology Co., Ltd., and were bred in the animal 
room (cleaning grade) of Experimental Animal Center 
of the People’s Liberation Army General Hospital. All 
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animal experiments were conducted in accordance with 
the provisions of Experimental Animal Committee of the 
People’s Liberation Army General Hospital.
Rats were randomly divided into six groups as fol-
lowed: (1) Sham control (not nephrectomized, injected 
with same dose of 1 × PBS); (2) Thy-1 (nephrectomized, 
injected with Thy-1 antibody); (3) Irb (nephrectomized, 
injected with Irb at the dose of 20 mg/kg body weight); 
(4) SHL (nephrectomized, injected with Shenhua Tablet 
at the dose of 0.75 g/kg body weight); (5) SHM (nephrec-
tomized, injected with Shenhua Tablet at the dose of 
1.5  g/kg body weight) and (6) SHH (nephrectomized, 
injected with Shenhua Tablet at the dose of 3 g/kg body 
weight). Each group has six mice. Seven days after unilat-
eral nephrectomy [22], the mice were given monoclonal 
Thy-1 antibody (2.5 mg/kg) via intravenous injection [23, 
24], which was performed once a week for 4 weeks [25] 
to induce chronic MsPGN. Twenty-one days after the last 
injection of Thy-1 antibody (W7), rats were daily treated 
with drugs (Irb or Shenhua Tablet) at the dose indicated 
above by gavage for 13 weeks. At each experimental time 
point, the Sham group was treated with CMC-Na solu-
tion alone for 13 weeks as well (Fig. 6).
Biochemical and histopathological approaches were 
taken to trace the progression of MsPGN for each group 
after the disease was induced by Thy-1 antibody. Urinary 
protein and serum creatinine in 24 h were tested every 2 
weeks. At the 18th week (the 13th week after drug inter-
vention), the 24 h urine was collected and the rats were 
then anesthetized with 2 % sodium pentobarbital (45 mg/
kg) by intraperitoneal injection. The rats were dissected 
and 8 ml of blood was collected to assess renal function 
and biochemical indicators of blood. The kidney was 
cut into several pieces; One of them was fixed with 4 % 
paraformaldehyde/PBS for pathological examination and 
another piece saved for immunostaining was embed-
ded in OCT (Optimal Cutting Temperature compound) 
and promptly frozen in liquid nitrogen and then stored 
at −80  °C; The rest of the kidney was directly frozen in 
liquid nitrogen and then stored at −80 °C. The changes in 
proteinuria, renal function and pathology were examined 
and the expression levels of p-Erk1/2, cyclin D1 and p21 
in the renal cortex were also tested.
Renal pathological examination
Kidneys were first fixed with 4  % paraformaldehyde/
PBS buffer, dehydrated with ethanol and then embed-
ded in paraffin. The kidneys were sectioned into slices 
of 4 μm thickness and PAS (Periodic Acid-Schiff) stain-
ing was performed to examine pathological changes 
under light microscope. The degree of renal impairment 
was semi-quantitatively and double-blindly scored by 
two pathologists following the published scoring system 
[26–29]. We randomly selected ten separate field for each 
specimen to evaluate lesions (400×  magnification), and 
averaged the values for the histological score.
Immunohistochemical analysis
The paraffin sections were fixed on polylysine-coated 
slides, deparaffined in xylene, and then rehydrated in 
ethanol of decreasing concentrations, and finally rinsed 
in water. Endogenous peroxidase was blocked with 3 % 
hydrogen peroxide at room temperature. The slices were 
then immersed in sodium citrate buffer (pH 6.0) and 
microwaved for 10 min. After being blocked with 1.5 % 
normal goat serum and incubated at room tempera-
ture for 20  min, the sections were stained with PCNA 
(Abcam; mouse monoclonal; 1: 500 dilution) antibody 
and incubated overnight at 4  °C. The following day, 
the unbound primary antibody was washed away with 
1  ×  PBS, then biotin-labeled secondary antibody was 
added and incubated at room temperature for 40  min. 
After being washed with 1 ×  PBS, horseradish peroxi-
dase conjugated streptavidin (Vectastain Elite ABC kit, 
Vector Labs, USA) was added and incubated at room 
temperature for an additional 40 min. After PBS wash, 
the sections were treated with DAB (chromogenic rea-
gent) for 5 min until the color turned brown and were 
then restained with hematoxylin as a last step. Kidney 
sections from three rats at each time point were used 
to quantify proliferative glomerular cells under high 
magnification microscope (400×) in a blind manner. 
Ten glomerluli were examined for each section. PCNA-
labeling index was calculated as “the number of PCNA-
positive cells divided by the total number of glomerular 
cells”.
Western blotting
The kidneys were lysed in RIPA buffer (50  mmol/L 
Tris-HCl, 150  mmol/L NaCl, 0.5  % deoxycholate, 1  % 
Nonidet P-40, 0.1  % SDS, 0.5  mM PMSF, 1  μg/ml leu-
peptin and 1  μg/ml aprotinin) on ice for 30  min, then 
centrifuged at 12,000 rpm at 4  °C for 30 min. The pro-
tein concentration was measured with Pierce BCA 
assay kit (Thermo Fisher Scientific, USA). Sixty to one-
hundred μg of total protein were loaded and run with 
12  % polyacrylamide gel. After electrophoresis, pro-
teins were transferred onto nitrate cellulose membrane. 
The membrane was first blocked with 5 % skim milk at 
room temperature for 1 h, and then incubated overnight 
at 4  °C with the primary antibodies against p-Erk1/2 
(mouse monoclonal, 1: 1000 dilution; Beyotime Insti-
tute of Biotechnology, China), cyclin D1 (mouse mono-
clonal, 1: 100 dilution; Santa Cruz, USA), p21 (mouse 
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monoclonal, 1: 5000 dilution; Novus Biologicals, USA) 
or β-actin (mouse monoclonal, 1: 5000 dilution; Sigma, 
USA) respectively. After incubation of individual pri-
mary antibody, the membrane was washed three times 
with TBST (Tris-Buffered Saline plus Tween 20) fol-
lowed by the incubation of secondary antibody for 1 h. 
The membrane was washed with TBST again and was 
then detected using an enhanced chemiluminescence 
(ECL) method. The intensity of proteins was quantified 
with Quantity One software (Bio-Rad, USA). All experi-
ments were repeated at least three times.
Statistical analysis
All data were processed with SPSS 15.0 software (SPSS 
Inc. USA). Charts were generated with Excel 2003. Data 
from continuous variables were expressed with (x¯ ±  s). 
The comparison between numerical variables was per-
formed with t test or ANOVA; Values were expressed as 
mean ± SD (Standard Deviation); p < 0.05 means statisti-
cally significant.
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